ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

Prescriber Checkup » Oregon » Cardiovascular Disease

Top Cardiovascular Disease Prescribers in Oregon

Top Prescribers

Providers are grouped by the primary specialty they listed when applying for a national health ID number. This doesn’t necessarily mean the person has special training or certification. Specialty is self-reported by providers and may have changed. Patients and claims shown are for Medicare Part D only.

Prescriber Claims Filled Total Cost Medicare Part D Patients Claims for Brand Name Drugs Schedule Two Schedule Three Dangerous Drugs to Seniors Brand Name Drugs Prescription Price
EUGENE SPEAR M.D.

Cardiovascular Disease

10,047

$242K

919
825 are 65+

1%
patients receiving schedule two controlled substances

Avg: 0%

2%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

14%
prescriptions for brand name drugs

Avg: 21%

$24
Average prescription price

Avg: $49

JAMES WASENMILLER MD

Cardiovascular Disease

9,694

$622K

803
742 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 21%

$64
Average prescription price

Avg: $49

WILLIAM STILES MD

Cardiovascular Disease

8,988

$395K

546
486 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 21%

$44
Average prescription price

Avg: $49

MAZIAR AZADPOUR M.D.

Cardiovascular Disease

7,826

$401K

754
663 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 21%

$51
Average prescription price

Avg: $49

MICHAEL TOREN M.D.

Cardiovascular Disease

7,487

$353K

471
444 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

24%
prescriptions for brand name drugs

Avg: 21%

$47
Average prescription price

Avg: $49

KIRK WALKER M.D.

Cardiovascular Disease

7,272

$315K

772
673 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 21%

$43
Average prescription price

Avg: $49

STEVEN PROMISLOFF M.D.

Cardiovascular Disease

7,053

$358K

400
367 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 21%

$51
Average prescription price

Avg: $49

HARMINDER GANDHOK M.D.

Cardiovascular Disease

6,792

$247K

680
579 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 21%

$36
Average prescription price

Avg: $49

KAMRAN GHALILI MD

Cardiovascular Disease

6,631

$216K

669
577 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 21%

$33
Average prescription price

Avg: $49

RICHARD WILSON MD

Cardiovascular Disease

6,238

$262K

508
454 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 21%

$42
Average prescription price

Avg: $49

RAGHUNANDAN KAMINENI MD

Cardiovascular Disease

5,658

$297K

542
453 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 21%

$52
Average prescription price

Avg: $49

DAVID SAENGER M.D.

Cardiovascular Disease

5,616

$336K

573
485 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

26%
prescriptions for brand name drugs

Avg: 21%

$60
Average prescription price

Avg: $49

RONALD CHELSKY M.D.

Cardiovascular Disease

5,566

$182K

581
516 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

17%
prescriptions for brand name drugs

Avg: 21%

$33
Average prescription price

Avg: $49

JAMES LOWRY MD

Cardiovascular Disease

5,174

$145K

399
349 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

2%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 21%

$28
Average prescription price

Avg: $49

KENT DAUTERMAN MD

Cardiovascular Disease

4,898

$254K

626
555 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 21%

$52
Average prescription price

Avg: $49

KENNETH LIGHTHEART M.D.

Cardiovascular Disease

4,873

$226K

500
440 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

20%
prescriptions for brand name drugs

Avg: 21%

$46
Average prescription price

Avg: $49

KATHERINE STRELICH M.D.

Cardiovascular Disease

4,808

$192K

421
371 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 21%

$40
Average prescription price

Avg: $49

BRADLEY PERSONIUS MD

Cardiovascular Disease

4,695

$231K

601
554 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

21%
prescriptions for brand name drugs

Avg: 21%

$49
Average prescription price

Avg: $49

ALAN HURTY M.D.

Cardiovascular Disease

4,565

$272K

418
377 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

3%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

27%
prescriptions for brand name drugs

Avg: 21%

$60
Average prescription price

Avg: $49

JOANNA NARKIEWICZ-JODKO M.D.

Cardiovascular Disease

4,497

$219K

280
244 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 21%

$49
Average prescription price

Avg: $49

ARMOND LAPINE M.D.

Cardiovascular Disease

4,382

$301K

513
451 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 21%

$69
Average prescription price

Avg: $49

JAY CHAPPELL M.D.

Cardiovascular Disease

4,325

$226K

530
483 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

23%
prescriptions for brand name drugs

Avg: 21%

$52
Average prescription price

Avg: $49

ROBERT MORSE D.O.

Cardiovascular Disease

4,257

$150K

394
337 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

16%
prescriptions for brand name drugs

Avg: 21%

$35
Average prescription price

Avg: $49

MAUREEN GOLDRING M.D.

Cardiovascular Disease

4,164

$175K

423
387 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

22%
prescriptions for brand name drugs

Avg: 21%

$42
Average prescription price

Avg: $49

BRIAN MORRISON M.D.

Cardiovascular Disease

4,135

$194K

447
385 are 65+

0%
patients receiving schedule two controlled substances

Avg: 0%

0%
patients receiving schedule three controlled substances

Avg: 0%

0%
prescriptions for patients 65+ for potentially dangerous drugs

Avg: 0%

18%
prescriptions for brand name drugs

Avg: 21%

$47
Average prescription price

Avg: $49

Sources

Centers for Medicare and Medicaid Services; National Technical Information Service; First Databank